LONDON, United Kingdom, June 18, 2026
LabGenius Therapeutics and LG Chem have entered into a multi-year research collaboration, option, and licensing agreement aimed at developing next-generation AI-designed multispecific antibodies for the treatment of solid tumors. The partnership combines LabGenius’ proprietary EVA™ artificial intelligence and machine learning-driven antibody discovery platform with LG Chem’s global life sciences development expertise to create novel tumour-targeting immunotherapies designed to improve efficacy while reducing toxicity. The collaboration seeks to address one of the most significant challenges in oncology drug development—delivering highly selective cancer therapies capable of targeting tumor cells while minimizing damage to healthy tissues. Through the agreement, the companies will focus on discovering and advancing a novel therapeutic candidate targeting a solid tumor antigen expressed across multiple difficult-to-treat cancer types, potentially opening new treatment opportunities for patients with limited therapeutic options.
AI and Machine Learning Power Next-Generation Antibody Discovery
The strategic alliance highlights the growing role of artificial intelligence, machine learning, robotic automation, and synthetic biology in transforming biopharmaceutical research. LabGenius will leverage its proprietary EVA™ platform, which integrates automated laboratory experimentation with advanced computational modeling to rapidly design, evaluate, and optimize multispecific antibodies. Unlike traditional drug discovery approaches, the platform continuously learns from experimental data, enabling researchers to identify antibody candidates with enhanced therapeutic characteristics more efficiently.
Company executives believe the collaboration validates the strength of LabGenius’ AI-enabled discovery capabilities and demonstrates increasing industry confidence in machine learning-driven drug development. By combining computational intelligence with biological experimentation, the partnership aims to accelerate the identification of highly selective oncology therapies capable of addressing unmet medical needs while improving safety profiles compared to existing immunotherapies.
Focus on Safer and More Effective Cancer Immunotherapies
Advertisement
A primary objective of the collaboration is to develop tumour-selective multispecific antibodies designed to overcome limitations associated with current cancer treatments, including on-target, off-tumour toxicities that can lead to unwanted side effects. The companies intend to create therapies that more precisely distinguish cancer cells from healthy tissues, potentially improving clinical outcomes while reducing treatment-related complications. Under the terms of the agreement, LabGenius will conduct preclinical research activities, including in vitro efficacy studies, before transferring the program to LG Chem for additional preclinical development and in vivo evaluation.
Following these studies, LG Chem will have the option to in-license the therapeutic candidate and advance it through further development. The approach reflects a growing industry trend toward highly targeted biologic therapies that leverage advances in immunology, precision medicine, and computational science to improve treatment effectiveness for patients with challenging cancers.
Strategic Collaboration Supports Long-Term Oncology Innovation
The agreement also represents an important commercial milestone for both organizations. LabGenius will receive an upfront payment, potential early development milestones, and, if the option is exercised, eligibility for triple-digit million-dollar clinical, regulatory, and commercial milestone payments, in addition to royalties on future net sales. LG Chem will fund all research and development activities conducted under the collaboration, reinforcing its commitment to expanding its oncology pipeline through innovative partnerships. Industry leaders from both companies emphasized the potential of combining cutting-edge AI technologies with advanced drug development expertise to accelerate the creation of transformative cancer treatments.
As demand grows for more effective and personalized immunotherapies, the collaboration positions LabGenius and LG Chem at the forefront of next-generation antibody engineering. The partnership further demonstrates how artificial intelligence is becoming an increasingly important driver of pharmaceutical innovation, enabling the discovery of novel therapies that may redefine future standards of cancer care.
Source: LabGenius Therapeutics, LG Chem press release
